sirtris pharmaceuticals stock price

And Sirtris/GSK faces long years of rigorous research before this nook of the anti-aging field yields a marketed drug. The $22.50 per Sirtris share that GSK paid as part of the deal represented a nearly 85 percent premium to Sirtris’ stock price at the time the deal was announced. Description. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. © 2021 TheStreet, Inc. All rights reserved. GBP11.33) per share followed by a second step merger in which any untendered Sirtris shares would be acquired at the same price per share. CEO Christoph Westphal and the management team will continue to lead the unit. Sirtris shares closed down 4% Tuesday prior to the news, at $12.23. Sirtris Pharmaceuticals ' first drug is a treatment for diabetes. Sirtris Pharmaceuticals is registered under the ticker NASDAQ:SIRT . document.write("
Click here to add this page to your favorites"); And Sirtris says it is close to launching clinical trials for experimental drugs that could prove to be up to 1,000 times more potent. if ((navigator.appVersion.indexOf("MSIE") > 0) && (parseInt(navigator.appVersion) >= 4)) { This stock price chart for SIRTRIS PHARMA INC., symbol SIRT, Nasdaq Stock Exchange is updated weekly. The planned purchase of the biopharma comes at a $10-a-share premium over Tuesday's closing price. Big pharma companies, pained by generic competition, have turned to licensing deals and acquisitions to bolster their pipelines. Sirtris Pharmaceuticals (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Sirtris Pharmaceuticals, Inc. SEC Form 4 Filed December 4, 2007: Statement of changes in beneficial ... Last Updated December 17, 2020 at 7:56 AM EST Back to Sirtris Pharmaceuticals, Inc. Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Too bad, since exactly happened what I had suggested: a big player is now trying to buy the company. A high-level overview of Sirtris Pharmaceuticals (SIRT) stock. News Corp is a network of leading companies in the worlds of diversified media, news, education, and information services READ MORE Prior to co-founding our company, Dr. Milne worked as head of discovery biology at Sirtris Pharmaceuticals, a biotechnology company, from 2004 to 2008, when it was acquired by GlaxoSmithKline. Markets Data Center: Biggest Price Gainers. Glaxo's shares edged up 9 cents, or 0.2% to $43.82 in recent post-market trading. [Updated 2:25 pm ET, 3/13/13] GlaxoSmithKline is closing down Cambridge, MA-based Sirtris Pharmaceuticals, almost five years after it paid $720 million to … //-->. Sirtris is the most high-profile shop working on sirtuins and resveratrol-like pharmacology, which subject has received a massive amount of … Sirtris Pharmaceuticals™ (NASDAQ: SIRT) is a biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with aging, including metabolic diseases such as Type 2 Diabetes. Developer of proprietary, orally administrable, small molecule biopharmaceutical drugs intended to cure type 2 diabetes, cancer, and other diseases. The proposed acquisition of Sirtris Pharmaceuticals (SIRT) is essentially aneffort to bolster GlaxoSmithKline's (NYSE:GSK)s pipeline in the Type 2 diabetes treatmentarea. Sirtris Pharmaceuticals has established a drug discovery capability to exploit sirtuin modulation for the treatment of human disease, an approach that has the potential to generate multiple clinically and commercially important products. Its SIRT-501, which is in early-stage development, is an enhanced formulation of resveratrol (the healthful agent found in red wine) that targets one of those enzymes, SIRT1.

Lasă un răspuns

Adresa ta de email nu va fi publicată. Câmpurile obligatorii sunt marcate cu *